TIDMAGL
Angle PLC
20 May 2022
For immediate release 20 May 2022
ANGLE plc ("the Company")
Prostate Cancer UK FUNDs new study using Parsortix
Research into the use of Parsortix-based CTC blood test to
assess whether prostate cancer patients require prostatectomy
surgery
Potential for a new standard of care in an area of high unmet
medical need
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, is pleased to announce that Prostate Cancer UK has
approved funding for a significant clinical study at Barts Cancer
Institute, Queen Mary University of London. The study will
investigate the use of the Parsortix(R) system to isolate
circulating tumour cells (CTCs) as a predictor of future disease
recurrence. Assessment of whether prostate cancer is likely to
progress, if this can be done reliably, may have a major bearing on
whether radical prostatectomy surgery is the most appropriate
treatment choice.
The trial is being funded by a GBP750,000 grant from Prostate
Cancer UK and will follow 200 men with localised prostate cancer
over five years. The aim of the study is to see whether the
presence of mesenchymal CTCs and CTC clusters in peripheral blood,
assessed using the Parsortix system, can predict whether the cancer
will eventually spread. The study has been designed and will be
conducted by Barts Cancer Institute and is being funded by Prostate
Cancer UK, both independently from ANGLE. ANGLE has agreed to
provide support for the study through the provision of Parsortix
instruments, cassettes and reagents.
The study will enrol patients who are due to have radical
prostatectomy surgery and will track them during and after
treatment. The researchers will take a blood sample before and at
regular intervals after the surgery and process the samples using
the Parsortix system seeking to identify those patients where
disease progression subsequently occurs. The design of this study
has been informed by earlier pilot studies independently conducted
at Barts Cancer Institute using the Parsortix system.
The trial is blinded, so the doctors treating the patients will
not know the outcome of the blood tests. If the Parsortix system
can be used to provide a predictive assessment of disease
progression despite radical prostatectomy, it could have a
significant impact on how prostate cancer is treated, making it
easier for doctors to choose the correct and most effective
treatment option.
Prostate cancer is the leading cause of cancer in men with 1 in
8 men diagnosed in their lifetime. In the UK more than 47,500 men
are diagnosed with prostate cancer each year and a further 400,000
are living with and after prostate cancer. At least 60% of prostate
cancers diagnosed are indolent and unlikely to cause harm during a
patient's lifetime. Nonetheless many men will undergo radical
prostatectomy which is associated with significant harms including
urinary incontinence and erectile dysfunction. There is equal risk
associated with undertreatment of aggressive disease and more than
11,500 men, or one man every 45 minutes dies from prostate cancer
in the UK each year. Liquid biopsy offers the potential for a much
safer, cost-effective diagnosis, active surveillance and, following
diagnosis, the ability to offer longitudinal monitoring and up to
date targeted treatment selection.
Yong-Jie Lu, lead researcher of the study and Professor of
Molecular Oncology at Barts Cancer Institute, Queen Mary University
of London, commented:
"If our hypothesis is correct, we hope that this blood test will
become the future standard of care for these patients. Patients
with localised prostate cancer will be treated more efficiently and
in a more personalised way, rather than surgically removing the
prostate and just waiting to see what happens. Doctors will have
more information about whether the cancer has really spread or not,
based on this test meaning patients won't be over or
under-treated."
Dr Hayley Luxton, Research Impact Manager at Prostate Cancer UK,
commented:
"We are delighted to support this trial which has the potential
to inform treatment decisions and improve outcomes for men living
with prostate cancer. Prostate cancer is the most common cancer in
men, killing 11,500 people each year in the UK. Being able to
identify aggressive cancer beforehand will help to ensure that men
are receiving the right treatment at the right time."
ANGLE Founder and Chief Executive, Andrew Newland, added:
"We are pleased that Barts Cancer Institute is progressing
investigation of clinical application of the Parsortix system in
prostate cancer and, independent form the Company, has secured
substantial funding from Prostate Cancer UK. Our aim is that the
Parsortix system will be widely adopted by third parties seeking
from their own initiative and funding to develop many and varied
uses of the Parsortix system to support cancer patients."
For further information:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Andrew Holder, Head of Investor Relations
Berenberg (NOMAD and Joint Broker)
Toby Flaux, Ciaran Walsh, Milo Bonser +44 (0) 20 3207 7800
Jefferies (Joint Broker)
Max Jones, Thomas Bective +44 (0) 20 7029 8000
FTI Consulting
Simon Conway, Ciara Martin +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 (212) 850 5624
For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with
sample-to-answer solutions. ANGLE's proven patent protected
platforms include a circulating tumor cell (CTC) harvesting
technology and a downstream analysis system for cost effective,
highly multiplexed analysis of nucleic acids and proteins.
ANGLE's cell separation technology is called the Parsortix(R)
system, and it enables a liquid biopsy (a simple blood test) to be
used to provide the cells of interest to the user in a format
suitable for multiple types of downstream analyses. The system is
based on a microfluidic device that captures cells based on a
combination of their size and compressibility. The system is
epitope independent and can capture all types of CTCs as well as
CTC clusters in a viable form (alive). CTCs enable the complete
picture of a cancer to be seen; as being an intact cell they allow
DNA, RNA and protein analysis and may provide comparable analysis
to a tissue biopsy. Because CTC analysis is a non-invasive process,
unlike tissue biopsy, it can be repeated as often as needed. This
is important because cancer develops and changes over time and
there is a clear medical need for up-to-date information on the
status of a patient's tumor. In addition, the live CTCs harvested
by the Parsortix system can be cultured, which offers the potential
for testing tumor response to drugs outside the patient.
The Parsortix technology is the subject of 26 granted patents in
Europe, the United States, China, Australia, Canada, India, Japan
and Mexico with three extensive families of patents are being
progressed worldwide.
The Parsortix system has a CE Mark in Europe for the indicated
use and, in the United States, a De Novo Submission has been made
to FDA for the Parsortix(R) PC1 system seeking FDA clearance with
Class II Classification for use with metastatic breast cancer
patients. FDA clearance is seen as the global standard. ANGLE is
seeking to be the first ever FDA cleared system for harvesting CTCs
for subsequent analysis.
ANGLE has also completed two separate 200 subject clinical
studies under a program designed to develop an ovarian cancer
pelvic mass triage test, with the results showing best in class
accuracy (AUC-ROC) of 95.1%. The pelvic mass triage assay has
undergone further refinement and optimisation and a 200 patient
clinical verification study has now completed enrolment.
ANGLE's technology for the multiplex evaluation of proteins and
nucleic acids of all types is called the HyCEAD(TM) platform and is
based on a patented flow through array technology. It provides for
low cost, highly multiplexed, rapid and sensitive capture of
targets from a wide variety of sample types. A proprietary
chemistry approach (the HyCEAD method) allows for the capture and
amplification of over 100 biomarkers simultaneously in a single
reaction. The HyCEAD system is extremely sensitive and is ideal for
measuring gene expression and other markers directly from Parsortix
harvests and was used in the ovarian cancer pelvic mass triage test
to achieve best in class accuracy (AUC-ROC) of 95.1%.
ANGLE's proprietary technologies can be combined to provide
automated, sample-to-answer results in both centralised laboratory
and point-of-use cartridge formats.
ANGLE has established formal collaborations with world-class
cancer centres and major corporates such as Abbott, Philips and
QIAGEN, and works closely with leading CTC translational research
customers. These Key Opinion Leaders (KOLs) are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. The body of evidence as to the benefits of the Parsortix
system is growing rapidly from our own clinical studies in
metastatic breast cancer and ovarian cancer and also from KOLs with
59 peer-reviewed publications and numerous publicly available
posters, available on our website.
ANGLE has established clinical services laboratories in the UK
and USA to accelerate commercialisation of the Parsortix system and
act as demonstrators to support product development. The
laboratories offer services to pharmaceutical and biotech customers
for use of Parsortix in cancer drug trials and, once the
laboratories are accredited and tests validated, will provide
Laboratory Developed Tests (LDTs) for patient management.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEAXSNFEKAEFA
(END) Dow Jones Newswires
May 20, 2022 02:01 ET (06:01 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024